Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy

NCT00474786 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00474786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00474786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2007
Completion date
January 31, 2013
Enrollment
512 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma